Ambalal Sarabhai Enterprises Limited (BOM:500009)
35.25
-0.75 (-2.08%)
At close: Nov 6, 2026
BOM:500009 Revenue
Ambalal Sarabhai Enterprises had revenue of 595.23M INR in the quarter ending September 30, 2026, with 33.91% growth. This brings the company's total for the last twelve months to 2.13B, up 8.22% year-over-year. In the fiscal year ending March 31, 2026, Ambalal Sarabhai Enterprises had annual revenue of 2.03B with 2.64% growth. That makes Ambalal Sarabhai Enterprises the 33,065th largest company in the world by revenue and 2,494th in India.
Revenue (ttm)
2.13B
Revenue Growth
+8.22%
P/S Ratio
1.27
Revenue / Employee
3.89M
Employees
547
Market Cap
2.70B
Revenue by Segment
Fiscal year ended Mar 31, 2026 See the full BOM:500009 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 2.03B | 52.02M | 2.64% |
| Mar 31, 2025 | 1.97B | 230.03M | 13.20% |
| Mar 31, 2024 | 1.74B | 32.87M | 1.92% |
| Mar 31, 2023 | 1.71B | -266.02M | -13.46% |
| Mar 31, 2022 | 1.98B | 324.75M | 19.66% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bilcare | 8.38B |
| Sat Kartar Life | 2.24B |
| Medicamen Biotech | 2.06B |
| Everest Organics | 1.92B |
| Gennex Laboratories | 1.78B |
| Jenburkt Pharmaceuticals | 1.71B |
| Astonea Labs | 1.48B |
| Accretion Pharmaceuticals | 1.01B |
Ambalal Sarabhai Enterprises News
- 7 months ago - EXCLUSIVE: Co-Diagnostics Expands South Asia Reach, Targets $13 Billion Market Opportunity - Benzinga